BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-4@catalystbrief.girapphe.com
DTSTAMP:20261117T024426Z
LAST-MODIFIED:20261117T024426Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Readout: Biohaven Ltd. (BHVN) — Taldefgrobep [H2 2027]
DESCRIPTION:Phase 2 topline data expected (monotherapy and GLP-1 combinatio
 n arms).\nSource: https://www.sec.gov/Archives/edgar/data/1935979/00019359
 7926000096/biohavencorporatepresent.htm\nhttps://catalystbrief.girapphe.co
 m/e/4?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/4?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
